Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2026 revenue of $80-83B. Eli Lilly’s Mounjaro revenue surged 110% to $7.4B in Q4. Zepbound revenue jumped 123% to $4 ...

Eli Lilly and Company (NYSE:LLY) is set to channel $1 billion into expanding contract manufacturing operations in India, with the goal of supplying medicines produced in the country to international ...

Eli Lilly makes the best-performing GLP-1 drugs on the market today. The company faces intense competition and has a relatively short window of opportunity. Wall Street is massively excited by the ...

Add Yahoo as a preferred source to see more of our stories on Google. A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience. The ...

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile ...

Eli Lilly has been busy building its drug pipeline for the future. The company currently sells the world's best-selling drug. It just bought Orna Therapeutics, an innovative drugmaker. Investing in ...

Too much of a good thing? Participants taking the highest dose of Eli Lilly’s new GLP-1 drug lost an average of 28.7% of their body weight in a late-stage trial, putting it on track to be a ...

Buddy Guy displays a youthful spirit during his Tiny Desk that makes you question if he really turns 90 this year. Once the music starts, his subtle speaking voice transforms into a mighty instrument, ...

CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...